Evidence map›Paper›PMID 37930509›Full record

ArticleMolecular biotechnology2024

Investigating the Molecular Interactions of Quinoline Derivatives for Antibacterial Activity Against Bacillus subtilis: Computational Biology and In Vitro Study Interpretations.

Anagha S Setlur, Chandrashekar Karunakaran, V Anusha, Aditya A Shendre, Akshay Uttarkar, Vidya Niranjan, H G Ashok Kumar, Raviraj Kusanur

Abstract read
PubMed Publisher
In one paragraph

Article in Molecular biotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Anagha S SetlurDepartment of Biotechnology, R.V College of Engineering, Bangalore, 560059, India.
Chandrashekar KarunakaranDepartment of Biotechnology, R.V College of Engineering, Bangalore, 560059, India.
V AnushaDepartment of Biotechnology, R.V College of Engineering, Bangalore, 560059, India.
Aditya A ShendreDepartment of Biotechnology, R.V College of Engineering, Bangalore, 560059, India.
Akshay UttarkarDepartment of Biotechnology, R.V College of Engineering, Bangalore, 560059, India.
Vidya NiranjanDepartment of Biotechnology, R.V College of Engineering, Bangalore, 560059, India.
H G Ashok KumarDepartment of Biotechnology, R.V College of Engineering, Bangalore, 560059, India.
Raviraj KusanurDepartment of Chemistry, R.V. College of Engineering, Bangalore, 560059, India. ravirajak@rvce.edu.in.ORCID http://orcid.org/0000-0001-6107-8475

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bacterial infections are evolving and one of the chief problems is emergence and prevalence of antibacterial resistance. Moreover, certain strains of Bacillus subtilis have become resistant to several antibiotics. To counteract this menace, the present work aimed to comprehend the antibacterial activity of synthesized two quinoline derivatives against Bacillus subtilis. Toxicity predictions via Protox II, SwissADME and T.E.S.T (Toxicity Estimation Software Tool) revealed that these derivatives were non-toxic and had little to no adverse effects. Molecular docking studies carried out in Schrodinger with two quinoline derivatives (referred Q1 and Q2) docked against selected target proteins (PDB IDs: 2VAM and1FSE) of B. subtilis demonstrated ideal binding energies (2VAM-Q1: - 4.63 kcal/mol and 2VAM-Q2: - 4.46 kcal/mol, and 1FSE-Q1: - 3.51 kcal/mol, 1FSE-Q2: - 6.34 kcal/mol). These complexes were simulated at 100 ns and the outcomes revealed their stability with slight conformational changes. Anti-microbial assay via disc diffusion method revealed zones of inhibition showing that B. subtilis was inhibited by both Q1 and Q2, with Q2 performing slightly better than Q1, pointing towards its effectiveness against this organism and necessitating further study on other bacteria in prospective studies. Thus, this study demonstrates that our novel quinoline derivatives exhibit antibacterial properties against Bacillus subtilis and can act as potent anti-bacterials.

Indexed as

Anti-Bacterial AgentsBacillus subtilisMolecular Docking SimulationQuinolinesBacterial ProteinsComputational BiologyMicrobial Sensitivity TestsAnti-Bacterial AgentsBacterial ProteinsquinolineQuinolinesAnti-microbial assay and zone of inhibitionComputational studiesFree-energy of bindingMolecular docking and simulationNovel quinoline derivativesToxicity predictions

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.